Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EPS (Weighted Average and Diluted) (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$0.73 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 7.35% to -$0.73 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.97, a 15.12% decrease, with the full-year FY2025 number at -$2.97, down 15.56% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.73 for Q4 2025 at Denali Therapeutics, up from -$0.74 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.32 in Q2 2023 to a low of -$0.87 in Q4 2023.
  • A 5-year average of -$0.58 and a median of -$0.68 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 375.0% in 2023, then plummeted 144.7% in 2024.
  • Denali Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.62 in 2021, then fell by 20.97% to -$0.75 in 2022, then fell by 16.0% to -$0.87 in 2023, then rose by 21.84% to -$0.68 in 2024, then fell by 7.35% to -$0.73 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's EPS (Weighted Average and Diluted) are -$0.73 (Q4 2025), -$0.74 (Q3 2025), and -$0.72 (Q2 2025).